Lombardy HTA Program issued final recommendations for three technologies in August 2026

The Lombardy Regional Health Technology Assessment Program supports evidence-based decisions on the introduction and appropriate use of health technologies within the regional healthcare system. This program involves several stages: technology identification, prioritization, assessment (HTA), and appraisal, with final recommendations for introduction. 

On August 27, 2026, following completion of the appraisal stage, the Regional HTA Commission issued final recommendations for three medical technologies. 

Two technologies received favorable opinions supporting their introduction into the regional healthcare system (appropriateness-of-use index exceeded the 0.50 acceptability threshold):

• Elecsys proBNP II for cardiovascular and heart failure risk stratification in patients with type 2 diabetes mellitus (appropriateness-of-use index of 0.55);
• Transfemoral osseointegrated prosthesis implantation for the rehabilitation of selected patients with transfemoral amputations who have failed or are intolerant of traditional socket prostheses (appropriateness-of-use index of 0.53).

One in vitro diagnostic technology received an unfavorable opinion.

This news is just one of about 300 market access news and updates collected by our team in the premium subscription service MTRC Access Intelligence every week from more than 80 organizations. Access our paid service to stay on top of all developments, specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, six-week, no-obligation trial.